Active Biotech AB Cash Flow-to-Debt Ratio
Active Biotech AB cash flow-to-debt ratio. Active Biotech AB (ACTI) has a Cash Flow-to-Debt Ratio of -0.84x as of June 2026, meaning its operating cash flow of Skr-9.00 Million could theoretically repay -1% of its total liabilities (Skr10.70 Million) in one year. Check Active Biotech AB (ACTI) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Active Biotech AB (2002–2025)
Cash flow-to-debt ratio of Active Biotech AB from 2002 to 2025. Historical debt coverage capacity for Active Biotech AB across 24 annual periods. Check ACTI cash reinvestment to operating cash ratio to assess the company's total reinvestment commitment from operating cash flow.
Active Biotech AB Cash Flow-to-Debt Ratio by Year (2002–2025)
Active Biotech AB cash flow-to-debt ratio by year from 2002 to 2025. Year-by-year debt coverage analysis for Active Biotech AB. For the full cash flow conversion analysis, see how efficiently does Active Biotech AB generate cash.
| Year | CF-to-Debt Ratio | Operating CF (SEK) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -2.22x | Skr-32.40 Million | Skr14.60 Million | ▲ +38.9% |
| 2024 | -3.63x | Skr-40.40 Million | Skr11.13 Million | ▼ -6.2% |
| 2023 | -3.42x | Skr-45.74 Million | Skr13.38 Million | ▼ -2.8% |
| 2022 | -3.33x | Skr-54.85 Million | Skr16.49 Million | ▲ +27.0% |
| 2021 | -4.56x | Skr-46.17 Million | Skr10.13 Million | ▼ -42.1% |
| 2020 | -3.21x | Skr-32.22 Million | Skr10.04 Million | ▼ -18.0% |
| 2019 | -2.72x | Skr-35.81 Million | Skr13.17 Million | ▼ -1335.0% |
| 2018 | -0.19x | Skr-40.65 Million | Skr214.52 Million | ▲ +7.7% |
| 2017 | -0.21x | Skr-46.45 Million | Skr226.14 Million | ▲ +35.3% |
| 2016 | -0.32x | Skr-73.16 Million | Skr230.32 Million | ▲ +60.8% |
| 2015 | -0.81x | Skr-217.89 Million | Skr268.84 Million | ▲ +3.7% |
| 2014 | -0.84x | Skr-267.09 Million | Skr317.21 Million | ▼ -198.4% |
| 2013 | -0.28x | Skr-102.25 Million | Skr362.40 Million | ▲ +58.1% |
| 2012 | -0.67x | Skr-240.40 Million | Skr356.82 Million | ▼ -411.4% |
| 2011 | -0.13x | Skr-46.97 Million | Skr356.53 Million | ▲ +78.4% |
| 2010 | -0.61x | Skr-196.32 Million | Skr321.34 Million | ▲ +15.8% |
| 2009 | -0.73x | Skr-224.77 Million | Skr309.86 Million | ▼ -40.7% |
| 2008 | -0.52x | Skr-159.46 Million | Skr309.34 Million | ▲ +17.2% |
| 2007 | -0.62x | Skr-186.70 Million | Skr299.97 Million | ▼ -149.9% |
| 2006 | -0.25x | Skr-100.13 Million | Skr402.04 Million | ▲ +49.4% |
| 2005 | -0.49x | Skr-192.51 Million | Skr391.05 Million | ▲ +50.5% |
| 2004 | -0.99x | Skr-149.65 Million | Skr150.59 Million | ▲ +80.8% |
| 2003 | -5.17x | Skr-288.83 Million | Skr55.82 Million | ▼ -54.7% |
| 2002 | -3.34x | Skr-291.71 Million | Skr87.24 Million | — |